bullish
Hugel Inc (145020 KS): Achieves Record High Revenue and Operating Profit in 4Q23
502 Views20 Feb 2024 09:30
Hugel reports revenue and operating profit growth of 4% and 22%, YoY, respectively, in 4Q23. The company plans to solidify position in domestic and international botulinum toxin markets.
Boomeranged on Tue, 5 Mar 2024 15:12
Hugel has received FDA approval for its botulinum toxin Letybo and becomes the only Korean company and one of the top 3 players globally that have approvals in three major aesthetic markets—the U.S., China, and Europe. Hugel aims to commercially launch the product in the U.S. by the middle of this year. FDA approval enhances our conviction on the growth prospect of the company.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
- Hugel Inc (145020 KS): Achieves Record High Revenue and Operating Profit in 4Q2320 Feb 2024
- Hugel Inc (145020 KS): Achieves Record High Revenue in 2Q23; Resubmits Marketing Application in US04 Oct 2023
- Hugel: A Solid Turnaround Story With Resumption of Botulax Sales in China27 Jun 2023
- Hugel Inc (145020 KS): Expanding Global Presence Provides Solace Amid Patent Tussle with Competitor27 Jun 2023
x